Average self-reported physical health ratings before or during the COVID-19 pandemic among individuals who engaged during the pandemic in more than 3 (A), 4 (B), or 5 (C) positive... by Elie Mulhem (22537863)

Subjects:

DataSheet_1_Nonclassical Monocytes Are Prone to Migrate Into Tumor in Diffuse Large B-Cell Lymphoma.docx by Simon Le Gallou (10742601)

“…<p>Absolute count of circulating monocytes has been proposed as an independent prognostic factor in diffuse large B-cell lymphoma (DLBCL). However, monocyte nomenclature includes various subsets with pro-, anti-inflammatory, or suppressive functions, and their clinical relevance in DLBCL has been poorly explored. …”

Raman spectroscopy was employed to investigate the conformational variations between wild-type and p.R163C mutant αB-crystallin proteins. by Aref Baharvand (21713886)

Subjects:

<i>In vivo</i> and long-term chaperone activity assessment of wild-type and p.R163C mutant αB-crystallin. by Aref Baharvand (21713886)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Decreased presence of tubulin-GFP at axonal MTs in a pulse chase experiment suggests changes in MT replenishment with age. by Pilar Okenve-Ramos (18150546)

IpaH9.8 mutants display decreased activity to degrade the GBPs. by Chenggong Ji (6858425)

Deletion of murine <i>Rhoh</i> leads to de-repression of <i>Bcl-6</i> via decreased KAISO levels and accelerates a malignancy phenotype in a murine model of lymphoma by Hiroto Horiguchi (3215001)

“…RHOH was initially identified as a translocation partner with BCL-6 in non-Hodgkin lymphoma (NHL), and aberrant somatic hypermutation (SHM) in the 5ʹ untranslated region of the RHOH gene has also been detected in Diffuse Large B-Cell Lymphoma (DLBCL). Recent data suggest a correlation between RhoH expression and disease progression in Acute Myeloid Leukaemia (AML). …”

Fig 1 - by Gláucia Helena Fernandes Seixas (5866511)

DataSheet_1_Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma.xlsx by Boram Lee (549836)

“…The genes most frequently altered (> 20%) were (in decreasing order of frequency) CDKN2A, PIM1, CD79B, TP53, MYD88, MYC, BTG2, BTG1, CDKN2B, DTX1, CD58, ETV6, and IRF4. …”

The nsP4-Q192L and C483Y mutations decrease the 4′-FlU sensitivity of both replication and transcription. by Peiqi Yin (6533747)

Thioflavin-T (ThT) fluorescence analysis of amyloid fibril formation in wild-type and p.R163C mutant αB-crystallin under thermochemical stress. by Aref Baharvand (21713886)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Decreased UFA/SFA ratio induces cytosolic chaperones. by Dongyeop Lee (108880)

“…<i>4</i> and <i>F44R5</i>.<i>5</i> may not be completely distinguishable because the sequences of these pairs of transcripts are very similar. …”

Foldases and holdases each decrease the level of unfolded protein. by Adam MR de Graff (9767829)

Silkworm ovaries and ovarioles infected by <i>N</i>. <i>bombycis</i>. by Chunxia Wang (766713)

Subjects:

The infection of follicle and nurse cells by <i>N</i>. <i>bombycis</i>. by Chunxia Wang (766713)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects: